Solid Biosciences has secured US FDA rare paediatric disease designation for SGT-212, its investigational gene therapy targeting FA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback